KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $7.4 million.

  • AbCellera Biologics' Cash from Financing Activities rose 134.40% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 13.86%. This contributed to the annual value of $12.8 million for FY2024, which is 23.30% up from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Cash from Financing Activities is $7.4 million, which was up 318.43% from -$3.4 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Cash from Financing Activities ranged from a high of $7.4 million in Q3 2025 and a low of -$5.1 million during Q2 2021.
  • Over the past 3 years, AbCellera Biologics' median Cash from Financing Activities value was $3.1 million (recorded in 2024), while the average stood at $3.0 million.
  • In the last 5 years, AbCellera Biologics' Cash from Financing Activities crashed by 1,566.76% in 2021 and then soared by 34,994.74% in 2023.
  • Over the past 5 years, AbCellera Biologics' Cash from Financing Activities (Quarterly) stood at $1.8 million in 2021, then tumbled by 80.97% to $349,000 in 2022, then spiked by 978.80% to $3.8 million in 2023, then climbed by 10.01% to $4.1 million in 2024, then spiked by 134.40% to $7.4 million in 2025.
  • Its Cash from Financing Activities stands at $7.4 million for Q3 2025, versus -$3.4 million for Q2 2025 and $6.0 million for Q1 2025.